Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8805379 | 0.80 | PTGS2 (0.40) | PTGS2KDM1ALMNA | |
| SCHEMBL3645796 | 0.80 | ADORA3 (0.51) | ADORA3ADORA2AADORA2BADORA1MAPT | |
| SCHEMBL3639306 | 0.79 | JAK2 (0.50) | ADORA3ADORA2AADORA2BADORA1MAPT | |
| SCHEMBL11332250 | 0.77 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1MAPT | |
| SCHEMBL14755486 | 0.75 | PTGS2 (0.49) | PTGS2 | |
| SCHEMBL11423635 | 0.73 | ADORA3 (0.56) | ADORA3ADORA2AADORA2BADORA1MAPT | |
| SCHEMBL20390138 | 0.73 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1MAPT | |
| SCHEMBL20390644 | 0.73 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1MAPT | |
| SCHEMBL9852272 | 0.73 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1MAPT | |
| SCHEMBL16238754 | 0.73 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2176247-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | Amgen Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2009009122-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | AMGEN INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009122-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | AMGEN INC. (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | ADORA3 189/4885ADORA2A 321/4885ADORA2B 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.